# An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

> **NCT00748358** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 50 (actual)

## Conditions studied

- Prostatic Neoplasms
- Neoplasms, Hormone-Dependent
- Tumor Markers, Biological
- Survival Rate
- Disease-Free Survival

## Interventions

- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT00748358
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748358, "An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00748358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*